Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Revenue (2020 - 2024)

Historic Revenue for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to $80.0 million.

  • Fulcrum Therapeutics' Revenue rose 899090.91% to $80.0 million in Q2 2024 from the same period last year, while for Mar 2025 it was $80.0 million, marking a year-over-year increase of 308725.1%. This contributed to the annual value of $80.0 million for FY2024, which is 275204.99% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Revenue stood at $80.0 million for Q2 2024, which was up 899090.91% from $871000.0 recorded in Q4 2023.
  • In the past 5 years, Fulcrum Therapeutics' Revenue registered a high of $80.0 million during Q2 2024, and its lowest value of $295000.0 during Q1 2023.
  • For the 5-year period, Fulcrum Therapeutics' Revenue averaged around $6.9 million, with its median value being $1.9 million (2022).
  • Its Revenue has fluctuated over the past 5 years, first crashed by 8861.88% in 2023, then surged by 899090.91% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Revenue (Quarter) stood at $4.2 million in 2020, then rose by 19.72% to $5.1 million in 2021, then crashed by 86.46% to $685000.0 in 2022, then rose by 27.15% to $871000.0 in 2023, then skyrocketed by 9084.85% to $80.0 million in 2024.
  • Its last three reported values are $80.0 million in Q2 2024, $871000.0 for Q4 2023, and $759000.0 during Q3 2023.